|Treatment-naïve patients with genotype 1 or 4 CHC||Sovaldi + peginterferon alfa + ribavirin||12 weeks|
|Patients with genotype 2 CHC||Sovaldi + ribavirin||12 weeks|
|Patients with genotype 3 CHC||Sovaldi + ribavirin||16 weeks*|
Here are Tuesday's top research calls, including upgrades for AutoZone and Eli Lilly, and downgrades for J.M. Smucker and Toll Brothers.
Stocks end Monday's session sharply lower as Wall Street grows restless ahead of the first presidential debate.